Company Overview and News

 
ARMO Biosciences Inc Shares Skyrocket on $1.6 B Eli Lilly Deal

2018-05-11 investorplace
ARMO Biosciences Inc (NASDAQ:ARMO) stock is skyrocketing today on news of a massive deal with Eli Lilly And Co (NYSE:LLY).

 
Stagnant Revenues Continue to Hamper the Growth of Pfizer Inc.

2018-05-02 investorplace
Pfizer Inc. (NYSE:PFE) stock tumbled after the New York-based pharma giant released earnings. Although the company beat earnings expectations, PFE revenue growth remained stagnant. This caused the stock to fall almost 5% as the stock price remained range bound.

 
Amid Mixed News on Earnings, Merck & Co., Inc. (MRK) Stock Remains Steady

2018-05-01 investorplace
Merck & Co., Inc. (NYSE:MRK) stock saw a tepid reaction as the company released earnings earlier in the morning. Wall Street expressed mixed reviews as the company beat estimates on earnings but disappointed on revenue growth.

 
Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?

2018-04-24 investorplace
It’s a busy week for pharmaceutical companies, with Eli Lilly And Co (NYSE:LLY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN) having released their earnings report today. For Eli Lilly stock, investors sought a definitive sign where the renowned firm was headed. Following a steep drop at the end of January, LLY has trended inside a frustrating consolidation pattern.

 
Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

2018-04-24 zacks
A smart beta exchange traded fund, the SPDR S&P Pharmaceuticals ETF (XPH - Free Report) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the U.S. equity market.

 
BRIEF-Lilly Says Galcanezumab Reduced Monthly Migraine Headache Days In Patients With Migraine

2018-04-24 reuters
* AAN 2018: LILLY‘S GALCANEZUMAB SIGNIFICANTLY REDUCED MONTHLY MIGRAINE HEADACHE DAYS IN PATIENTS WITH MIGRAINE WHO PREVIOUSLY FAILED TO RESPOND TO MULTIPLE PREVENTIVE THERAPIES

2
5 Drug Stocks Poised to Surpass on Earnings This Quarter

2018-04-17 investorplace
The first-quarter earnings season has just kicked off. Per the latest Earnings Preview, the bottom line of S&P 500 companies is expected to increase at a highly impressive rate of 16.6% on a year-over-year basis. This prospective upside marks the maximum quarterly earnings growth pace in seven years.

 
Radius Health Down on Negative CHMP Opinion for Lead Drug

2018-03-23 zacks
Shares of Radius Health (RDUS - Free Report) fell 4% after the company suffered a setback once again in Europe.

 
Radius Health Announces Positive Data on Lead Drug Tymlos

2018-03-19 zacks
Radius Health, Inc. (RDUS - Free Report) announced positive results from the phase III study, ACTIVExtend, at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo in Chicago.

 
BRIEF-EFSD, JDRF And Lilly Extend Collaboration Supporting Type 1 Diabetes Research

2018-03-08 reuters
* ELI LILLY AND CO - EFSD, JDRF AND CO AGREED TO EXTEND COLLABORATION FOR EUROPEAN PROGRAMME IN TYPE 1 DIABETES RESEARCH THROUGH 2020 Source text for Eikon: Further company coverage:

 
BRIEF-Boehringer Ingelheim And Lilly Expand Heart Failure Program For Jardiance

2018-03-06 reuters
* BOEHRINGER INGELHEIM AND LILLY EXPAND HEART FAILURE PROGRAM FOR JARDIANCE® WITH NEW EXERCISE CAPACITY TRIALS

 
BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer

2018-02-26 reuters
* LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIOTM (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER

 
BRIEF-Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz

2018-02-13 reuters
* LILLY ANNOUNCES POSITIVE TOP-LINE PHASE 3 RESULTS FOR TALTZ® (IXEKIZUMAB) IN ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS)

 
BRIEF-Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14

2018-01-31 reuters
* ELI LILLY - RECORDED ESTIMATED CHARGE OF $1.9 BILLION IN QUARTER ASSOCIATED WITH U.S. TAX REFORM LEGISLATION, CHARGES ASSOCIATED WITH REDUCING COST STRUCTURE

1
Radius Health to Get Third Day-180 List of Outstanding Issues

2017-12-18 zacks
Radius Health, Inc. (RDUS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) will provide a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...